HSPA2-AS1: A Potential Drug Target and Biomarker (G102723809)

Target Name: HSPA2-AS1

NCBI ID: G102723809

HSPA2-AS1

Other Name(s): HSPA2 and ZBTB1 antisense RNA 1

HSPA2-AS1: A Potential Drug Target and Biomarker

HSPA2-AS1 (HSPA2 and ZBTB1 antisense RNA 1) is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. HSPA2-AS1 is a splicing exon that is located between the HSPA2 gene and the ZBTB1 gene on chromosome 6p21.2. It is a small non-coding RNA molecule that contains 19 amino acid residues and has been shown to play a role in the regulation of gene expression.

HSPA2-AS1 functions as an antisense RNA molecule that specifically binds to the pre-mRNA of HSPA2 gene and prevents it from being translated into protein. This process is known as RNA-protein interactions and is a well-known mechanism for regulating gene expression in various organisms.

Expression and function of HSPA2-AS1

HSPA2-AS1 is a highly expressed gene in most tissues and cells, and its expression level is regulated by various factors, including DNA binding factors, RNA binding factors, and post-transcriptional modifications. HSPA2-AS1 has been shown to play a role in the regulation of gene expression in various tissues and cells, including the brain, muscle, liver, and pancreas.

In the brain, HSPA2-AS1 has been shown to be involved in the regulation of neuronal excitability and synaptic plasticity. Studies have shown that HSPA2-AS1 can modulate the expression of genes involved in neurotransmitter synthesis, release, and uptake, such as dopamine, GABA, and serotonin. HSPA2-AS1 has also been shown to play a role in the regulation of neuronal differentiation and plasticity, as well as in the regulation of synaptic strength and neurotrophic factors.

In muscle, HSPA2-AS1 has been shown to play a role in the regulation of muscle protein synthesis and gene expression. Studies have shown that HSPA2-AS1 can modulate the expression of genes involved in muscle protein synthesis, such as myosin heavy chain (MHC) genes, and can also regulate the expression of genes involved in muscle fiber type determination, such as the myofibroblast gene.

In the liver, HSPA2-AS1 has been shown to play a role in the regulation of gene expression involved in drug metabolism and detoxification. Studies have shown that HSPA2-AS1 can modulate the expression of genes involved in drug metabolism, such as cytochrome P450 enzymes, and can also regulate the expression of genes involved in detoxification, such as the aryl hydrocarbon receptor gene.

In pancreas, HSPA2-AS1 has been shown to play a role in the regulation of gene expression involved in insulin secretion. Studies have shown that HSPA2-AS1 can modulate the expression of genes involved in insulin secretion, such as the insulin gene.

Drug targeting and biomarker potential

HSPA2-AS1 has been shown to be a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. HSPA2-AS1 has been shown to play a role in the regulation of gene expression involved in cell survival, angiogenesis, and inflammation, as well as in the regulation of signaling pathways involved in cell growth and differentiation.

One potential mechanism for targeting HSPA2-AS1 is to use small molecules or drugs that can modulate its expression or function. For example, small molecules such as RNA interference (RNAi) drugs can be used to knockdown HSPA2-AS1 expression and reduce its levels in the cell. Similarly, drugs that can modulate the activity of HSPA2-AS1, such as

Protein Name: HSPA2 And ZBTB1 Antisense RNA 1

The "HSPA2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HSPA2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets